Psilocybin
What you gain
Clearer illness-related anxiety trial data than Spravato.
What it asks of you
Self-pay and limited everyday-anxiety evidence.
Comparison guide
Psilocybin or Spravato for Anxiety
Spravato’s FDA label is for depression — not primary anxiety. Psilocybin’s best anxiety studies are in cancer-related distress.
Answers at a glance
Comprehensive comparison
Psilocybin
Best-studied on a weeks timescale in cancer-related distress.12
Spravato
Not established for primary anxiety — the label and main trials target depression.3
Psilocybin
Illness-related trials followed people across weeks to months.12
Spravato
No approved anxiety durability data on the label.
Psilocybin
Nothing daily to stop.
Spravato
Stopping follows depression maintenance rules — not an anxiety taper plan.
Psilocybin
Usually one supported dosing day plus prep and integration.12
Spravato
Depression visit schedule only — twice weekly at first, then less often.3
Psilocybin
OR/CO guided courses often about $850–$4,500+.5
Spravato
Clinic visit pricing; anxiety coverage is unlikely.6
Psilocybin
Almost never.
Spravato
Unlikely unless billed under covered depression care.3
Psilocybin
Good studies in cancer-related anxiety; less for everyday worry.12
Spravato
Not labeled for anxiety. Related ketamine-family research exists; Spravato itself is a depression medicine.34
References & sources
- 1Griffiths et al. (2016). Psilocybin for cancer-related anxiety and depression. View study →
- 2Ross et al. (2016). Psilocybin for cancer-related anxiety and depression. View study →
- 3FDA. SPRAVATO labeled uses (depression — not primary anxiety). View study →
- 4Hartland et al. (2023). Combined review of ketamine-family anxiety effects. View study →
- 5Oregon Health Authority. Accessing psilocybin services. View study →
- 6Typical Spravato clinic cash estimates (market reporting). View study →
Typical US ranges and outcomes; your care depends on screening and clinical need. Not medical advice.
Considerations
Every path has a trade
Spravato
What you gain
Clinic access when depression is also present.
What it asks of you
No anxiety indication and unlikely coverage for anxiety alone.